Back to top

PerkinElmer Posts Decent 2Q; Up Y-Y

Read MoreHide Full Article

PerkinElmer ((PKI - Free Report) reported second quarter 2012 adjusted (excluding one-time expenses) earnings per share of 53 cents, beating the corresponding Zacks Consensus Estimate of 48 cents.

Net income from continuing operations in the reported quarter was $33.6 million (or 29 cents per share), up 12.3% year over year.


Revenues came in at $521.8 million in the reported quarter, up 8.9% year over year, but missing the Zacks Consensus Estimate of $537 million.

Growth was aided by an extended product portfolio comprising innovative and improved offerings from PerkinElmer. Revenues grew 5% year over year on an organic basis after adjustment for acquisitions which contributed 8% to the growth in revenues in the quarter and a 4% drop after accounting for foreign currency.

Segment Analysis

Human Health segment revenues were $258.4 million, up 18.1% (up 4% on an organic basis) year over year. Revenues from the Environmental Health segment amounted to $263.4 million in the quarter, up 1.2% (up 5% on an organic basis).  


Adjusted gross margin was 49.3% in the second quarter, up 210 basis points year over year. Adjusted operating margin was 16.9%, up 240 basis points on a year-over-year basis.  

Adjusted operating margin at the Human Health segment was 21.6%, up 130 basis points year over year. Adjusted operating margin at the Environmental Health segment was 15.9%, up 210 basis points from the year-ago quarter.

Balance Sheet

PerkinElmer ended the second quarter with cash and cash equivalents of $171.4 million, down 56.6% year over year. Long-term debt was $911 million, up 35.8%. Cash flow from continuing operations increased almost 41% year over year to $77.4 million in the quarter.


For 2012, PerkinElmer reaffirmed its guidance for organic revenue to increase in the mid-single digits. The company continues to expect adjusted earnings per share of about $2 to $2.05 for 2012. PerkinElmer revised its forecasts for reported earnings per share in a range of $1.21 to $1.26 compared with the prior guidance in the band of $1.27 to $1.32.

PerkinElmer has established itself as a market leader, particularly in the genetic screening segment, and holds one of top two market share positions in several important subsets of the life sciences technology and genetic screening businesses.

The company continues to execute well across all its product lines aided by rebounding markets and cost containment efforts. PerkinElmer’s transfer of select manufacturing to China has expanded its operating margins. The company has increased its productivity and improved product mix in favor of higher value added products, resulting in higher operating margins.

PerkinElmer, however, operates in a highly competitive industry characterized by rapid technological change and evolving industry standards. As a result, the company would have to make large investments in R&D in order to retain a competitive pipeline. PerkinElmer competes with Thermo Fisher Scientific (TMO - Free Report) among others.

PerkinElmer's exposure to poor end market visibility might result in a relatively unattractive risk-reward trade-off for the stock. Our Neutral recommendation is supported by a short-term Zacks #3 Rank (Hold).

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Thermo Fisher Scientific Inc (TMO) - free report >>

PerkinElmer, Inc. (PKI) - free report >>

More from Zacks Analyst Blog

You May Like